Agnieszka Góral

ORCID: 0000-0002-7324-9718
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • Ubiquitin and proteasome pathways
  • Genomics, phytochemicals, and oxidative stress
  • Heat shock proteins research
  • Vitamin C and Antioxidants Research
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Protease and Inhibitor Mechanisms
  • Healthcare and Venom Research
  • Histone Deacetylase Inhibitors Research
  • Yersinia bacterium, plague, ectoparasites research
  • T-cell and B-cell Immunology
  • Acute Myeloid Leukemia Research
  • S100 Proteins and Annexins
  • Neonatal Respiratory Health Research
  • RNA regulation and disease
  • RNA Research and Splicing
  • Immune cells in cancer
  • Redox biology and oxidative stress
  • Parkinson's Disease Mechanisms and Treatments
  • Vitamin D Research Studies
  • Protein Structure and Dynamics
  • Nanoparticles: synthesis and applications
  • Retinoids in leukemia and cellular processes
  • RNA and protein synthesis mechanisms

Medical University of Warsaw
2018-2023

Instytut Biologii Doświadczalnej im. Marcelego Nenckiego
2014-2021

Polish Academy of Sciences
2016-2021

Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-based therapies have transformed cancer treatment. Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1high tumors. Our study provides new information on the efficacy such an approach against PD-L1low targets.New atezolizumab-based was generated introduced T, NK, or NK-92 cells. Breast MDA-MB-231 MCF-7 cell lines non-malignant cells (HEK293T, HMEC, MCF-10A, BM-MSC) were...

10.1136/jitc-2021-002500 article EN cc-by Journal for ImmunoTherapy of Cancer 2022-01-01

Abstract Oxidative stress, caused by the imbalance between reactive species generation and dysfunctional capacity of antioxidant defenses, is one characteristic features cancer. Here, we quantified hydrogen peroxide in tumor microenvironment (TME) demonstrated that concentrations are elevated interstitial fluid isolated from murine breast cancers vivo, when compared with blood or normal subcutaneous fluid. Therefore, investigated effects increased concentration on immune cell functions. NK...

10.1158/2326-6066.cir-20-1023 article EN cc-by-nc-nd Cancer Immunology Research 2021-12-01

L-ascorbate (L-ASC) is a widely-known dietary nutrient which holds promising potential in cancer therapy when given parenterally at high doses. The anticancer effects of L-ASC involve its autoxidation and generation H2O2, selectively toxic to malignant cells. Here we present that thioredoxin antioxidant system plays key role the scavenging extracellularly-generated H2O2 B-cells. We show inhibition peroxiredoxin 1, enzyme removes system-dependent manner, increases sensitivity B-cells L-ASC....

10.1016/j.redox.2018.11.020 article EN cc-by-nc-nd Redox Biology 2018-11-29

B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a genetically heterogeneous blood cancer characterized by abnormal expansion of immature B cells. Although intensive chemotherapy provides high cure rates in majority patients, subtypes harboring certain genetic lesions, such as MLL rearrangements or BCR‐ABL1 fusion, remain clinically challenging, necessitating search for other therapeutic approaches. Herein, we aimed to validate antioxidant enzymes the thioredoxin system potential...

10.1002/1878-0261.12476 article EN cc-by Molecular Oncology 2019-03-12

The Hsp90 chaperone activity is tightly regulated by interaction with many co-chaperones. Since CacyBP/SIP shares some sequence homology a known co-chaperone, Sgt1, in this work we performed set of experiments order to verify whether can interact Hsp90. By applying the immunoprecipitation assay have found that binds and middle (M) domain responsible for binding. Furthermore, proximity ligation (PLA) on HEp-2 cells has shown CacyBP/SIP-Hsp90 complexes are mainly localized cytoplasm these...

10.1371/journal.pone.0156507 article EN cc-by PLoS ONE 2016-06-01

Abstract The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-Lineage Leukemia ( MLL ) gene rearrangements (MLLr BCP-ALL) is still extremely poor. Inhibition of anti-apoptotic protein BCL-2 venetoclax emerged as a promising strategy this subtype BCP-ALL, however, lack sufficient responses in preclinical models and the possibility developing resistance exclude using monotherapy. Herein, we aimed to uncover potential mechanisms responsible limited activity MLLr...

10.1038/s41388-022-02196-y article EN cc-by Oncogene 2022-01-28

Abstract Background Impaired neutrophil activity is an important issue in chronic lymphocytic leukemia (CLL), as it contributes to a dysfunctional immune response leading life-threatening infections patients. Some features typical of CLL neutrophils, e.g., the B-cell-supportive secretion profile, have already been described. However, most these studies were performed on cells isolated from peripheral blood. It still unclear which molecular factors and cell types are involved shaping function...

10.1186/s40164-023-00452-9 article EN cc-by Experimental Hematology and Oncology 2023-10-10

10.1016/j.biocel.2014.09.015 article EN The International Journal of Biochemistry & Cell Biology 2014-09-22

PhLP2 is a small cytosolic protein that belongs to the highly conserved phosducin-like family of proteins. In amniote genomes there are two homologs, PhLP2A and PhLP2B. It has been shown mammalian modulates CCT/TRiC chaperonin activity during folding cytoskeletal order better understand function in cellular quality control system, present study we have searched for its targets. Applying immunoprecipitation followed by mass spectrometry analysis identified Hsp90 as partner PhLP2A. With pull...

10.1002/jcb.25669 article EN Journal of Cellular Biochemistry 2016-08-06

10.1016/j.biocel.2018.04.012 article EN The International Journal of Biochemistry & Cell Biology 2018-04-13

Regulatory T cells (Tregs) are capable of inhibiting the proliferation, activation and function play an important role in impeding immune response to cancer. In chronic lymphocytic leukemia (CLL) a dysfunctional elevated percentage effector-like phenotype Tregs have been described. this study, using Eµ-TCL1 mouse model CLL, we evaluated changes their expansion at different stages progression. Importantly, show that depletion DEREG mice triggered new anti-leukemic cytotoxic cell clones...

10.3389/fimmu.2022.781364 article EN cc-by Frontiers in Immunology 2022-02-28

The SGT1 protein is highly expressed in the mammalian brain, particularly neurons of hippocampus and cortex, Purkinje cells cerebellum. There are literature data indicating that may be involved pathogenesis neurodegenerative disorders such as Parkinson’s disease (PD). In present work we have found protected from toxicity rotenone, an agent evokes behavioral histopathological symptoms PD. To gain more insight into possible mechanism underlying protective action looked at α-synuclein...

10.3390/biom11111675 article EN cc-by Biomolecules 2021-11-11

Białko CacyBP/SIP występuje w różnych komórkach i tkankach ssaków, a jego wysoki poziom notowany jest mózgu, śledzionie, grasicy oraz wielu nowotworach. oddziałuje z wieloma białkami efektorowymi, tym cytoszkieletu: aktyną, tubuliną, tropomiozyną. Wskazuje to, iż bierze udział procesach komórkowych, którym towarzyszą zmiany organizacji cytoszkieletu zarówno warunkach fizjologicznych jak też stanach chorobowych. W niniejszej pracy przedstawiono charakterystykę oddziaływania rolę tych...

10.36921/kos.2018_2373 article PL Kosmos 2018-07-11

Background: B‐cell acute lymphoblastic leukemia (B‐ALL) is a heterogeneous hematological disorder characterized by accumulation of B cell precursors. Although undeniable improvement has been made in the therapy B‐ALL (>90% pediatric patients experience remission), there are still specific subtypes associated with poor outcome. Among such mixed lineage rearrangements (MLLr ALL) or BCR‐ABL1 fusion protein (BCR‐ABL1+ ALL). Importantly, MLLr ALL does not respond to novel immunotherapies, thus...

10.1097/01.hs9.0000558860.58207.fb article EN cc-by-nc-nd HemaSphere 2019-06-01
Coming Soon ...